Delivering translational research through the MRC Confidence in Concept (CiC) scheme
Lead Research Organisation:
University of Bristol
Department Name: UNLISTED
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Technical Summary
The Confidence in Concept (CIC) scheme is a key part of MRC’s translational research strategy and provides annual awards to institutions to flexibly support a portfolio of early stage translational research projects. CIC is designed to accelerate the transition from discovery research to viable translational projects by supporting preliminary studies to establish proof-of-concept so that the approach will then become competitive for more substantial translational funding.
People |
ORCID iD |
| Description | Innovator Award |
| Amount | £925,000 (GBP) |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 09/2021 |
| End | 08/2023 |
| Description | NIHR/UKRI COVID Urgency grant AERATOR |
| Amount | £450,000 (GBP) |
| Organisation | National Institute for Health Research |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2021 |
| End | 04/2022 |
| Description | VEGFC gene manipulation to protect from diabetic nephropathy |
| Amount | £215,000 (GBP) |
| Organisation | Diabetes UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 12/2021 |
| End | 03/2023 |
| Title | ambulatory dynamic endocrine diagnostics |
| Description | : We propose to revolutionise current endocrine diagnostics by replacing conventional, timeconsuming single-analyte hormone assays with ambulatory dynamic endocrine diagnostics. Disorders of endocrine systems are not only accompanied by changes in absolute hormone levels, but also secretion patterns. The rapid circadian (24 hour) and ultradian (< 24 hour) cycling of hormone levels poses diagnostic challenges since random measurements do not always detect abnormalities. Furthermore, monitoring of treatment of endocrine diseases are often severely limited by lack of multiple measurements at different time points. To overcome these hurdles academic and commercial partners propose to validate novel dynamic endocrine diagnostics with state-or-the-art ultrasensitive assays by liquid chromatography tandem mass spectroscopy (LCMS/MS) and multiplex proximity extension assays .These will be able to generate a timeline of "hormonomes" covering the 24 hour cycle without losing sensitivity and specificity, producing not only hormone levels, but also secretion patterns for diagnostics and monitoring purposes. |
| Type Of Material | Physiological assessment or outcome measure |
| Year Produced | 2020 |
| Provided To Others? | No |
| Impact | N/A |
| Description | Cell and gene therapy expert advice on platelets innovation |
| Organisation | Cell and Gene Therapy Catapult |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Development of a novel scalable system to generate platelets for transfusion |
| Collaborator Contribution | advice on scaling up from the Cell & Gene Therapy Catapult via their Commercialisation of Research scheme |
| Impact | Project is ongoing |
| Start Year | 2022 |
| Description | Partnership with Ceryx Medical |
| Organisation | Ceryx Medical Ltd |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Feasibility, safety and efficacy of a novel device restoring respiratory sinusarrhythmia in a novel ovine model of dyssynchronous ischaemic heart failure |
| Collaborator Contribution | Potential commercial partner providing advice on translational pathway |
| Impact | Project has not completed yet |
| Start Year | 2022 |
| Title | NOVel patIent shielD (NOVID) for dental procedures |
| Description | NOVel patIent shielD (NOVID) for dental procedures |
| IP Reference | 2110319.7 |
| Protection | Patent application published |
| Year Protection Granted | 2021 |
| Licensed | No |
| Impact | Too early |